UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November 8, 2004
GENTA
INCORPORATED
(Exact Name of Registrant
as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
| 0-19635 | 33-0326866 | ||
| (Commission File Number) | (IRS Employer Identification No.) | ||
| Two
Connell Drive Berkeley Heights, NJ |
07922 | ||
| (Address of Principal Executive Offices) | (Zip Code) |
(908) 286-9800
(Registrant’s
Telephone Number, Including Area Code)
(Former Name or
Former Address, if Changed Since Last Report)
Item 1.02
Termination of a Material Definitive Agreement.
On
November 8, 2004, Genta Incorporated (“Genta”) issued a press release
announcing that the Company has received from Aventis notice of termination
of the agreements between Genta and Aventis, part of the sanofi-aventis Group,
regarding the development and commercialization of Genasense® (oblimersen
sodium) Injection. The press release is attached hereto as Exhibit 99.1 and
incorporated herein by reference.
Item 2.02
Results of Operations and Financial Condition.
On
November 9, 2004, Genta issued a press release reporting the results of its
operations for the three months ended September 30, 2004. The press release
is attached hereto as Exhibit 99.2 and incorporated herein by reference.
Item 8.01 Other
Events.
On
November 8, 2004, Genta issued a press release announcing results of the Company’s
randomized Phase 3 clinical trial of Genasense® (oblimersen sodium) Injection
in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
The press release is attached hereto as Exhibit 99.3 and incorporated herein
by reference.
| Exhibit Number |
Description | |
| |
|
|
| 99.1 | Press Release dated November 8, 2004 | |
| 99.2 | Press Release dated November 9, 2004 | |
| 99.3 | Press Release dated November 8, 2004 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
| GENTA INCORPORATED | ||||
| Date: | November 9, 2004 | By: | /s/ William P. Keane | |
| |
|
|||
| Name: |
William P. Keane | |||
| Title: | Vice President, Chief Financial Officer and Corporate Secretary | |||
EXHIBIT INDEX
| Exhibit Number |
Description |
Sequentially Numbered Page |
|
| 99.1 | Press Release dated November 8, 2004 | ||
| 99.2 | Press Release dated November 9, 2004 | ||
| 99.3 | Press Release dated November 8, 2004 |